LeMaitre Vascular, Inc. (NASDAQ:LMAT) Chairman George W. Lemaitre sold 30,000 shares of the stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $33.65, for a total value of $1,009,500.00. Following the transaction, the chairman now directly owns 3,436,808 shares of the company’s stock, valued at $115,648,589.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of LeMaitre Vascular, Inc. (NASDAQ LMAT) traded down 0.44% during midday trading on Friday, hitting $33.96. The company had a trading volume of 224,228 shares. The firm has a market capitalization of $645.99 million, a P/E ratio of 48.51 and a beta of 0.65. The stock has a 50 day moving average price of $31.57 and a 200 day moving average price of $27.77. LeMaitre Vascular, Inc. has a 1-year low of $16.80 and a 1-year high of $36.09.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 EPS for the quarter, topping the consensus estimate of $0.17 by $0.06. The business had revenue of $25.80 million for the quarter, compared to analysts’ expectations of $25.42 million. LeMaitre Vascular had a net margin of 14.19% and a return on equity of 15.02%. The business’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.14 EPS. On average, equities analysts anticipate that LeMaitre Vascular, Inc. will post $0.80 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Wednesday, August 23rd will be given a dividend of $0.055 per share. This represents a $0.22 annualized dividend and a dividend yield of 0.65%. The ex-dividend date of this dividend is Monday, August 21st. LeMaitre Vascular’s dividend payout ratio is 31.88%.

LeMaitre Vascular announced that its Board of Directors has initiated a stock repurchase plan on Thursday, July 27th that allows the company to buyback $7.50 million in outstanding shares. This buyback authorization allows the medical instruments supplier to repurchase up to 1.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s management believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) Chairman Sells 30,000 Shares of Stock” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/19/insider-selling-lemaitre-vascular-inc-nasdaqlmat-chairman-sells-30000-shares-of-stock-updated.html.

Several brokerages have weighed in on LMAT. Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a report on Tuesday, August 1st. Stifel Nicolaus restated a “buy” rating and set a $32.00 target price (up previously from $29.00) on shares of LeMaitre Vascular in a research report on Sunday, July 30th. Benchmark Co. downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Monday, July 10th. They noted that the move was a valuation call. Canaccord Genuity downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating and set a $28.00 target price on the stock. in a research report on Monday, July 10th. Finally, Craig Hallum initiated coverage on LeMaitre Vascular in a research report on Tuesday, June 6th. They set a “hold” rating and a $31.00 target price on the stock. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. LeMaitre Vascular presently has an average rating of “Buy” and an average price target of $30.17.

Several hedge funds have recently made changes to their positions in the stock. Bahl & Gaynor Inc. boosted its stake in shares of LeMaitre Vascular by 12.3% in the first quarter. Bahl & Gaynor Inc. now owns 48,585 shares of the medical instruments supplier’s stock valued at $1,197,000 after buying an additional 5,320 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of LeMaitre Vascular by 52.3% in the first quarter. Ameriprise Financial Inc. now owns 201,508 shares of the medical instruments supplier’s stock valued at $4,963,000 after buying an additional 69,186 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of LeMaitre Vascular by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 88,552 shares of the medical instruments supplier’s stock valued at $2,181,000 after buying an additional 1,408 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of LeMaitre Vascular by 27.7% in the first quarter. American Century Companies Inc. now owns 192,732 shares of the medical instruments supplier’s stock valued at $4,747,000 after buying an additional 41,848 shares in the last quarter. Finally, Algert Global LLC increased its position in shares of LeMaitre Vascular by 93.9% in the first quarter. Algert Global LLC now owns 62,062 shares of the medical instruments supplier’s stock valued at $1,529,000 after buying an additional 30,062 shares during the last quarter. Hedge funds and other institutional investors own 67.12% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Stock Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related stocks with our FREE daily email newsletter.